TP53 or also known p53 functiondeletion/mutation

By SWA

TP53 (also known as p53) is a critical tumor suppressor gene that plays a crucial role in preventing the development of cancer. Mutations and deletions in the TP53 gene are among the most common genetic alterations found in various types of cancers. Here's some information about TP53 mutations and deletions:

  1. TP53 Gene Function: The TP53 gene encodes a protein called p53, which acts as a transcription factor. It regulates the cell cycle, DNA repair, and apoptosis (programmed cell death). When cells experience DNA damage or other stressors, p53 becomes activated and can initiate repair mechanisms or trigger apoptosis if the damage is too severe. In this way, p53 helps prevent the proliferation of damaged cells that could lead to cancer.

  2. TP53 Mutations: Mutations in the TP53 gene can lead to loss or alteration of p53 protein function. These mutations can be either germline (inherited from one's parents) or somatic (acquired during one's lifetime). Germline TP53 mutations are associated with Li-Fraumeni syndrome, a rare genetic disorder that significantly increases the risk of various cancers. Somatic TP53 mutations are commonly found in a wide range of cancer types, including breast, lung, colorectal, and ovarian cancers, among others.

  3. TP53 Deletions: Deletions involving the TP53 gene typically result in the loss of one copy of the gene in affected cells. This is known as a "loss of heterozygosity" event. It reduces the cell's ability to produce functional p53 protein and impairs its ability to respond effectively to DNA damage or other cellular stresses. TP53 deletions are also frequently found in various cancer types.

  4. Consequences of TP53 Mutations/Deletions: TP53 mutations and deletions can have several consequences:

    • Impaired DNA Repair: Cells with dysfunctional p53 may have reduced capacity to repair DNA damage, leading to the accumulation of mutations.

    • Uncontrolled Cell Proliferation: Loss of p53 function can result in uncontrolled cell division, leading to tumor formation and growth.

    • Resistance to Apoptosis: Cells lacking functional p53 may evade apoptosis, allowing potentially cancerous cells to survive and proliferate.

    • Therapeutic Implications: TP53 mutations and deletions can impact the response of cancer cells to various treatments, including chemotherapy and radiation therapy. Some therapies are designed to specifically target p53-deficient cancer cells.

  5. Clinical Significance: The presence of TP53 mutations or deletions in cancer cells is often associated with a poorer prognosis, as these alterations can confer resistance to treatment and a more aggressive tumor phenotype. Researchers and clinicians are actively studying TP53 status to develop targeted therapies and improve cancer treatment outcomes.

    Testing for p53 is important in both research and clinical settings, as it helps understand the status and functionality of this crucial tumor suppressor protein. Below are some common methods used to test for p53:

    1. Immunohistochemistry (IHC)

  6. What it tests: Detects the presence and amount of p53 protein in tissue samples.
  7. How it works:
    • Uses antibodies specific to p53 to stain tissue sections.
    • A pathologist examines the stained tissue under a microscope to assess p53 expression levels.
  8. Use case: Commonly used in cancer diagnosis to check for abnormal p53 overexpression, which may indicate a p53 mutation.
  9. Limitation: Overexpression doesn't always mean the protein is functional; mutated p53 often accumulates in cells.

2. Genetic Testing (Sequencing)

  • What it tests: Looks for mutations in the TP53 gene, which encodes the p53 protein.
  • How it works:
    • Extract DNA from tissue or blood samples.
    • Use methods like PCR (Polymerase Chain Reaction) and Next-Generation Sequencing (NGS) to identify mutations in the TP53 gene.
  • Use case: Determines if p53 mutations are present, which is critical for prognosis and targeted therapies.
  • Limitation: Only detects mutations, not protein functionality or expression levels.

3. Western Blotting

  • What it tests: Measures the amount of p53 protein in a sample.
  • How it works:
    • Proteins are extracted from cells or tissues and separated by gel electrophoresis.
    • A specific antibody detects p53, and its signal is visualized on a blot.
  • Use case: Commonly used in research to measure p53 expression or its activation in response to DNA damage.
  • Limitation: Requires fresh or frozen samples, not applicable to fixed tissues.

4. Functional Assays

  • What it tests: Assesses whether p53 is functional in inducing its downstream effects (e.g., cell cycle arrest or apoptosis).
  • How it works:
    • Treat cells with DNA-damaging agents (e.g., radiation, chemotherapy).
    • Measure p53 activation and target gene expression (e.g., p21, BAX) using techniques like qPCR, Western blot, or flow cytometry.
  • Use case: Research settings to evaluate how well p53 responds to DNA damage.
  • Limitation: Labor-intensive and usually not used in clinical diagnostics.

5. ELISA (Enzyme-Linked Immunosorbent Assay)

  • What it tests: Quantifies the p53 protein in a sample.
  • How it works:
    • Uses p53-specific antibodies to detect and measure p53 levels in biological samples like serum or cell lysates.
  • Use case: Research or biomarker studies to detect circulating p53 in cancer patients.
  • Limitation: Cannot differentiate between wild-type and mutated p53.

6. RNA Analysis (RT-PCR or RNA-Seq)

  • What it tests: Measures the mRNA levels of the TP53 gene.
  • How it works:
    • Extract RNA from cells or tissues.
    • Use quantitative PCR (qPCR) or RNA sequencing (RNA-Seq) to assess TP53 gene expression.
  • Use case: Research studies to correlate TP53 expression with other cellular processes.
  • Limitation: High mRNA levels may not correlate with functional protein levels.

7. p53 Reporter Assays

  • What it tests: Evaluates p53’s ability to activate transcription of its target genes.
  • How it works:
    • Insert a reporter gene (e.g., luciferase or GFP) under the control of a p53-responsive promoter into cells.
    • Measure reporter activity to determine p53 functionality.
  • Use case: Research to study p53's transcriptional activity.
  • Limitation: Requires genetic modification of cells, so it’s not used clinically.

8. Cytogenetic Testing (e.g., FISH)

  • What it tests: Looks for deletions or amplifications in the TP53 gene region on chromosome 17.
  • How it works:
    • Fluorescence in situ hybridization (FISH) uses fluorescent probes to detect changes in the gene’s location or copy number.
  • Use case: Identifying structural abnormalities in TP53, particularly in cancers like leukemia or lymphoma.
  • Limitation: Cannot detect point mutations.

Clinical Context

  • Normal Function: Wild-type (normal) p53 regulates cell cycle, DNA repair, and apoptosis.
  • Mutated p53: Mutations in TP53 are linked to poor prognosis in many cancers.
  • Testing helps guide treatment strategies, such as identifying patients who may benefit from therapies targeting mutant p53 or synthetic lethality approaches.

Testing for p53 can involve protein-based methods (IHC, Western blot), DNA-based methods (sequencing, FISH), or functional assays. The choice of test depends on whether the goal is to detect p53 expression, mutations, or functional .

Understanding the genetic status of TP53 in cancer patients is crucial for determining treatment strategies and predicting disease outcomes. 

When p53 is mutated, which is common in many cancers, it can lose its ability to suppress tumors—or even promote cancer growth. This makes p53 an important focus for cancer treatments. Current strategies include developing drugs that restore normal p53 function, blocking proteins that inactivate p53, or targeting cancer cells that lack functional p53 through synthetic lethality approaches. p53 is critical for protecting our DNA and preventing cancer, and therapies targeting its pathways hold great promise for fighting tumors.

Latest reference,
27 November 2024

Unraveling the Guardian: p53’s Multifaceted Role in the DNA Damage Response and Tumor Treatment Strategies
https://www.mdpi.com/1422-0067/25/23/12928

© 2000-2025 Sieglinde W. Alexander. All writings by Sieglinde W. Alexander have a fife year copy right.
Library of Congress Card Number: LCN 00-192742
ISBN: 0-9703195-0-9 

 

Comments

Post a Comment

Popular posts from this blog

Toxic Skin Condition Post-mRNA COVID-19 Vaccination

By SWA
Image
Identifying Severe Skin Conditions Post-Vaccination Following administration of the BioNTech mRNA vaccine, a small subset of individuals may develop severe and complex reactions. These reactions are often misdiagnosed or misunderstood due to their rarity and diverse presentation. This essay examines a case characterized by severe skin conditions, systemic symptoms, and complications such as hypercalcemia and crystal formation. It highlights the need for accurate diagnosis, holistic management, and increased awareness of these rare but significant vaccine-related adverse events. Initial Symptoms and Misdiagnoses Severe symptoms began shortly after the first dose of the BioNTech vaccine, initially presenting as petechiae, diagnosed by a rheumatologist. However, following the second dose, symptoms rapidly escalated, resulting in intense burning pain and thinning of the skin. The skin on the legs and thighs became paper-thin and could tear with the slightest touch, with the affected area e...
Read more

Dysferlin Protein: Key Roles, Genetic Locations

By SWA
Image
The purpose of this article is to share and discuss the details of a new discovery, which is highlighted within: CRISPR-Cas9: A Breakthrough Tool to Repair the DYSF Gene The dysferlin protein plays an essential role in maintaining the integrity of muscle cell membranes, particularly in tissues that endure significant mechanical stress, such as skeletal and cardiac muscles . Encoded by the DYSF gene , dysferlin is indispensable for repairing damaged cell membranes after injury caused by muscle contraction or external forces. This article explores the main locations where dysferlin is produced, its role in muscle repair, and supportive nutritional and therapeutic strategies for individuals with dysferlin deficiency, such as those affected by dysferlinopathies (e.g., Limb-Girdle Muscular Dystrophy Type 2B or Miyoshi Myopathy). Currently, there is no definitive answer as to why the severity of dysferlin protein expression or depletion varies. Do pathogens play a role in the methylation o...
Read more

Is ME CFS connected to Spinal Muscular Atrophy (SMA) or Post Polio?

By SWA
Image
Today, I understand why Spinal Muscular Atrophy (SMA) received little attention, particularly in the mid-50s. This complex and debilitating genetic illness was poorly understood, and patients' symptoms were often minimized or even dismissed. For more information, please visit the Spinal Muscular Atrophy (SMA) page on MalaCards . Even now, many neurologists lack detailed knowledge of SMA, and comprehensive examinations mentioned in research are rarely pursued. In 2008, while investigating permanent adrenal insufficiency, an MRI ordered by my endocrinologist unexpectedly revealed Chiari Malformation II. However, surgery in 2009 brought no improvement. In 2010, a DNA test showed a genetic marker in the ACTN3 gene: https://www.malacards.org/search/results?q=ACTN3%20gene%20and%20Spinal%20Muscular%20Atrophy%20(SMA) A 2015 MRI revealed ankylosing spondylitis, multiple Tarlov cysts, stenosis at L4 and L5, spinal canal narrowing, and widespread degenerative changes. Surgery on L4 and L5 ...
Read more